Investors can contact the law firm at no cost to learn more about recovering their losses ​LOS ANGELES, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Pliant Therapeutics, Inc. (“Pliant Therapeutics, Inc.” or “the Company”) (NASDAQ:PLRX) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Pliant Therapeutics, Inc. investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. I ...

Pliant Therapeutics, Inc. PLRX stock is trading lower on Monday.On Friday, during after-hours trading, Pliant Therapeutics announced it has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF), a chronic lung disease that causes scarring and stiffening of the lung tissue. Patients currently enrolled in BEACON-IPF will remain in the trial.The move follows a prespecified data review and recommendations by the tria ...

Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase 2b trial and will monitor current patients while data is reviewed SOUTH SAN FRANCISCO, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board (DSMB), the Company has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase ...

Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase 2b trial and will monitor current patients while data is reviewed SOUTH SAN FRANCISCO, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendations by the trial’s independent Data Safety Monitoring Board (DSMB), the Company has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase ...

Dr. Imbert brings 25 years of strategic clinical to commercial-stage manufacturing and drug development experience SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Delphine Imbert, Ph.D. as Chief Technical Officer. Dr. Imbert brings 25 years of product development, process optimi ...

Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, CA., November 7, 2024 - Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage clinical biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported th ...

Former Bristol Myers Squibb Global Medical Affairs Lead brings over 25 years of experience to Pliant SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Gary Palmer, M.D., MBA as Senior Vice President of Medical Affairs. Dr. Palmer will lead the Company's global medical affairs acti ...

Core Insights - Pliant Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for fibrotic diseases [1][4] - The company will participate in several investor events in September 2024, including the Wells Fargo Healthcare Conference, H.C. Wainwright Global Investment Conference, Cantor Global Healthcare Conference, and Stifel Virtual Immunology and Inflammation Summit [2] Company Overview - Pliant Therapeutics is recognized as a leader in the discovery and development of therapeutics for fibrotic diseases [4] - The lead product candidate, bexotegrast (PLN74809), is an oral small molecule that acts as a dual selective inhibitor of αvß6 and αvß1 integrins, targeting idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC) [4] - Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the FDA for both IPF and PSC, as well as Orphan Drug Designation from the European Medicines Agency [4] - Pliant has initiated the BEACON-IPF trial, an adaptive Phase 2b/3 study for bexotegrast in IPF [4] - The company is also conducting a Phase 1 study for PLN-101095, a small molecule targeting solid tumors, and has received regulatory clearance for a Phase 1 study of PLN-101325, a monoclonal antibody for muscular dystrophies [4]

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced four upcoming presentations at the European Respiratory Society (ERS) International Congress 2024. The Congress will take place in Vienna, Austria from September 7 - 11, 2024. Late Breaker - Oral and ePoster Presentations Title: Evaluation of the ant ...

Bexotegrast at 320 mg was well tolerated up to 40 weeks of treatment with no treatment-related severe or serious adverse events Statistically significant improvement in alkaline phosphatase (ALP) levels over 24 weeks compared to placebo Continued improvement in hepatocyte function and bile flow by contrast MRI imaging observed from Week 12 to Week 24 SOUTH SAN FRANCISCO, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced positive 24-week data from the 320 mg co ...